Navigation Links
Apexigen, Inc. Announces Collaboration for Antibody Discovery
Date:12/7/2010

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs.  Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.  While financial details were not disclosed, Apexigen will receive an upfront license fee, and is eligible to receive future milestone and royalty payments if certain development and commercialization milestones are achieved.

Apexigen's antibody technologies produce a broad diversity of antibodies with high specificity, high affinity, and unique epitopes, and can successfully generate antibodies against challenging antigens where competing technologies fail. This enables the development of 'best-in-class' therapeutic antibodies.  

"We're excited about this collaboration and look forward to working closely with Centocor R&D," said Dr. Xiaodong Yang, President & CEO of Apexigen.  "Our goal is to become a world leader in the development of best-in-class therapeutic antibodies.  To achieve this goal, we plan to collaborate with partners while also developing our own product pipeline."

About Apexigen

Apexigen, Inc. is a biopharmaceutical company focused on the discovery and development of best-in-class therapeutic antibodies.  Apexigen has exclusive rights to the proprietary antibody technologies that were developed by Epitomics, Inc. for the development and commercialization of human therapeutics. In addition, Apexigen assumed development and commercialization responsibility for a pipeline of therapeutic product programs initiated by Epitomics.

Located in Burlingame, CA, Apexigen is actively developing its internal therapeutic product pipeline and seeking to form collaborative relationships with pharmaceutical and biotechnology companies for the discovery and development of pharmaceutical products based on its humanized rabbit monoclonal antibody technologies.  More information about Apexigen is available at www.apexigen.com.Contact Mark Nevins, Vice President, Business DevelopmentTel: 650-931-6236, ext. 502Email:  mnevins@apexigen.com
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
2. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
3. China Medical Technologies, Inc. Announces the Closing of US$150 Million Convertible Senior Note Offering and the Completion of Repurchase of US$105.9 Million Convertible Notes Due 2011
4. ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
5. China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program
6. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
7. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
8. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
9. Ascension Orthopedics Announces Implantation of the TITAN™ Modular Total Shoulder
10. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
11. Curemark Announces Four New Sites Participating in Autism Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):